Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01480232 · ClinicalTrials.gov registry record · Phase 2
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
A Phase 2 study, sponsored by A. Eden Evins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT01480232: Clinical Trial Phase 2 study, sponsored by A. Eden Evins.
NCT01480232 is a Phase 2 study that was terminated before completion, run by A. Eden Evins. The registered enrollment target is 345 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01480232, a Phase 2 study, was terminated before completion, sponsored by A. Eden Evins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
Primary Outcome
Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) \<10 ppm and/or urine cotinine \<50 ng/mL.
Interventions
- DRUG Placebo Capsule
- DRUG EVP-6124
- DRUG NicoDerm Patch (Active)
- DRUG NRT Patch (Placebo)
- BEHAVIORAL Brief Supportive and Behavioral Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT01480232 stopped before completion
NCT01480232 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo Capsule is the first listed.
NCT01480232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01480232 about?
NCT01480232 is a clinical study titled "A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence". This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
What is the current status of trial NCT01480232?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2011-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01480232?
The interventions under investigation include: Placebo Capsule (DRUG), EVP-6124 (DRUG), NicoDerm Patch (Active) (DRUG), NRT Patch (Placebo) (DRUG), Brief Supportive and Behavioral Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01480232?
This trial is sponsored by A. Eden Evins, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01480232's enrollment target sits among peer trials
345 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia